Janssen Biotech

What Janssen Biotech does

Janssen Biotech, Inc. (formerly Centocor Biotech) is the specialty biopharmaceutical subsidiary of Johnson & Johnson (NYSE: JNJ), developing and commercializing innovative biologic and small-molecule medicines across oncology, immunology, neuroscience, infectious diseases, pulmonary hypertension, and cardiovascular/metabolic disease. Founded in 1979 and headquartered operationally across Horsham and Lower Gwynedd Township, Pennsylvania, and Raritan, New Jersey, the company employs 10,000+ people and operates a portfolio of FDA-approved therapies including IMAAVY (FcRn blocker for generalized myasthenia gravis and wAIHA), RYBREVANT/LAZCLUZE (EGFR/MET bispecific plus TKI for first-line EGFR-mutated NSCLC), ERLEADA and AKEEGA (androgen receptor and PARP inhibitor combinations in prostate cancer), TREMFYA (IL-23 inhibitor across psoriasis, PsA, ulcerative colitis, and Crohn's disease), DARZALEX/DARZALEX FASPRO (anti-CD38 monoclonal antibody used in 748,000+ patients worldwide), CARVYKTI (BCMA-directed CAR-T partnered with Legend Biotech, 30-month OS exceeding 85%), TALVEY (GPRC5D bispecific for multiple myeloma), BALVERSA (FGFR3 inhibitor), and Simponi (TNF-alpha inhibitor); partnered pipeline assets include icotrokinra, an oral IL-23 receptor peptide in-licensed from Protagonist Therapeutics, with tiered royalties of 6–10% on net sales.

The company's underlying technology platforms span monoclonal antibodies, bispecific antibodies, CAR-T cell therapy, FcRn receptor blockade, IL-23 and CD38 pathways, and PARP inhibition, with manufacturing capabilities including a $1 billion next-generation cell therapy plant under construction in Pennsylvania (500+ biomanufacturing jobs, 4,000 construction jobs) and an expanded CARVYKTI footprint in Raritan, NJ.

Janssen Biotech generates revenue primarily through global sales of its proprietary pharmaceutical products (DARZALEX, ERLEADA, TREMFYA, RYBREVANT, IMAAVY) distributed via hospital and specialty pharmacies (hospital pharmacies alone account for 54.7% of ERLEADA distribution), supplemented by royalty and licensing income from partners including Genmab (DARZALEX royalties — $3,672M in worldwide net sales in Q3 2025), Halozyme (ENHANZE subcutaneous delivery technology), and Protagonist (icotrokinra milestones and tiered royalties). The company is wholly owned by J&J — itself a public conglomerate — and benefits from parent-level global commercial infrastructure, R&D scale, and capital deployment (including a $55B U.S. investment commitment through early 2029), while operating with strategic autonomy on pipeline, manufacturing, and partnership decisions.

Name

Janssen Biotech

Legal name

Janssen Biotech

Website

https://janssenbiotech.com

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Janssen Biotech, a Johnson & Johnson subsidiary founded in 1979, develops and commercializes innovative biologic and small-molecule therapies across oncology, immunology, and neuroscience — spanning monoclonal antibodies, bispecifics, CAR-T, and FcRn inhibitors — distributed globally through hospital and specialty pharmacy channels.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Monoclonal antibody therapies
• Oncology pharmaceuticals
• Immunology biologics
• CAR-T cell therapies
• Biopharmaceutical medicines

Headquarters

HQ city

Horsham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Pharmaceutical product sales: Janssen Biotech generates revenue primarily through global sales of proprietary pharmaceutical products including DARZALEX, ERLEADA, TREMFYA, RYBREVANT, IMAAVY, and other approved therapies across oncology, immunology, and neuroscience.
2. Royalty and licensing revenue: DARZALEX generates significant royalty revenue under the Genmab licensing agreement, with worldwide net sales of $3,672 million in Q3 2025. Janssen Biotech maintains 82.4% market share in the ERLEADA market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Janssen Biotech develops, manufactures, and commercializes innovative biologic medicines and cell therapies — including monoclonal antibodies, bispecific antibodies, CAR-T cell therapies, and FcRn inhibitors — targeting serious diseases in oncology, immunology, and neuroscience. The company's portfolio spans regulatory-approved specialty medicines (DARZALEX, ERLEADA, RYBREVANT, TREMFYA, IMAAVY, CARVYKTI, AKEEGA, TALVEY, BALVERSA, LAZCLUZE) sold through global hospital and specialty pharmacy channels.

Product overview

Janssen Biotech, a Johnson & Johnson subsidiary, offers a diverse portfolio of pharmaceutical products spanning oncology, immunology, neuroscience, and infectious diseases. Key products include IMAAVY (FcRn blocker for myasthenia gravis and wAIHA), RYBREVANT (EGFR-targeted bispecific for lung cancer), TREMFYA (IL-23 inhibitor for inflammatory conditions), DARZALEX (CD38 antibody for multiple myeloma), and CARVYKTI (CAR-T cell therapy co-developed with Legend Biotech). The portfolio includes small molecule therapies (ERLEADA, AKEEGA, BALVERSA), bispecific antibodies (talquetamab), and partnered programs (icotrokinra with Protagonist). Janssen maintains manufacturing operations including a $1 billion cell therapy facility in Pennsylvania.

Differentiator

Problem solved

Functional benefit

Products and services

• IMAAVY (nipocalimab-aahu) An FcRn blocker antibody therapy for generalized myasthenia gravis and warm autoimmune hemolytic anemia that targets the neonatal Fc receptor to reduce pathogenic autoantibodies driving disease.
• ERLEADA (apalutamide) An androgen receptor inhibitor for prostate cancer treatment, used in perioperative setting for high-risk localized or locally advanced disease before and after surgery.
• RYBREVANT (amivantamab-vmjw)

Quantifiable outcome

• IMAAVY achieved greater reductions in MG-ADL scores (-4.9 vs -2.7) in generalized myasthenia gravis patients early in disease course
• +7 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Monte Rosa TherapeuticsminorStrategic or Co-development Partner · 16 March 2026Clinical supply agreement to evaluate MRT-2359 in combination with ERLEADA (apalutamide) for treating metastatic castration-resistant prostate cancer with AR mutations. Planned Phase 2 trial in up to 25 patients.
• Biocon BiologicsminorChannel Partner/ Reseller/ Distributor · 1 January 20242024 deal for biosimilar commercialization. Biocon Biologics received rights to commercialize biosimilar products in select markets, leveraging India's cost-efficient manufacturing capabilities and biologics expertise.
• Legend BiotechcoreStrategic or Co-development Partner · 1 November 2023November 2023 license agreement for DLL3-targeted CAR-T cell therapies. Legend Biotech retains responsibility for ongoing U.S. Phase 1 trial while Novartis holds exclusive worldwide rights for other development, manufacturing, and commercialization. Expanded CARVYKTI manufacturing capacity at Janssen's Raritan, New Jersey facility. CARVYKTI demonstrated 30-month overall survival rates exceeding 85% in multiple myeloma.
• Protagonist TherapeuticscoreStrategic or Co-development Partner · 1 January 20172017 collaboration agreement for ICOTYDE (icotrokinra), the first and only IL-23 receptor targeted oral peptide for psoriasis. Protagonist eligible for $50 million milestone payment plus 6-10% tiered royalties on net sales and up to $580 million in additional regulatory and sales milestones. FDA NDA submitted in July 2025.
• Novartis Pharma AGminorStrategic or Co-development PartnerDLL3-targeted CAR-T licensing arrangement where Legend Biotech retained U.S. Phase 1 rights while Novartis holds exclusive worldwide rights for other development, manufacturing, and commercialization.

Scale indicators6 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• AstraZeneca: Major oncology competitor with Tagrisso in EGFR-mutated NSCLC (directly competing with RYBREVANT + LAZCLUZE), expanding hematology and rare disease franchises via Alexion, and growing bispecific antibody platform.
• Bristol Myers Squibb: Large oncology and immunology competitor with overlapping franchises in multiple myeloma (Empliciti, Pomalyst), immunology (Zeposia, Sotyktu), and CAR-T cell therapy (Breyanzi, Abecma). Directly competes with Janssen's DARZALEX, TREMFYA, and CARVYKTI.
• Merck & Co. Keytruda dominates immuno-oncology and is increasingly combined with targeted therapies in NSCLC, including EGFR-mutated settings where RYBREVANT competes. Merck's pipeline and combination strategies directly overlap with Janssen's oncology franchise.
• Roche / Genentech: Oncology and immunology peer with bispecific antibody leadership (Hemlibra, Vabysmo, Columvi), large multiple myeloma presence, and overlapping neuroscience and rare disease programs. Directly competes across most of Janssen's therapeutic areas.
• Amgen: Biologics-heavy peer with Tezspire competing in respiratory/inflammatory diseases, Blincyto and Imdelltra in hematology, and a bispecific T-cell engager platform (Imdelltra) overlapping TALVEY in multiple myeloma.
• Pfizer: Post-Seagen acquisition, Pfizer is a major oncology competitor with PADCEV and Tukysa overlapping Janssen's solid tumor franchise. Also competes in hematology (Elrexfio) and has a growing immunology and bispecific antibody presence.
• Novartis: Cell therapy pioneer (Kymriah) and now holds exclusive worldwide rights (ex-US Phase 1) to DLL3-targeted CAR-T licensed from Legend Biotech/Janssen partnership. Direct competitor in CAR-T and large oncology competitor across hematology and solid tumors.
• AbbVie: Immunology leader with Skyrizi and Rinvoq directly competing against TREMFYA in psoriasis, psoriatic arthritis, and IBD. Also competes in oncology (Imbruvica, Venclexta) and has deep hematology presence overlapping with Janssen's multiple myeloma franchise.
• Sanofi: Immunology leader with Dupixent competing in inflammatory diseases against TREMFYA, plus rare disease (Sarclisa competing with DARZALEX in multiple myeloma) and oncology pipeline expansion.

Emerging players

• Regeneron: Immunology and oncology peer with Dupixent (with Sanofi) competing in inflammatory diseases, plus Libtayo in oncology and growing bispecific antibody efforts. Comparable R&D-driven biologics model with overlapping therapeutic area focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Janssen Biotech